Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Lone W MadsenPeer B ChristensenUlrik FahnøeMartin S PedersenJens BukhAnne ØvrehusPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
In this pilot study of 4-week treatment with GLE/PIB with and without ribavirin, we found that baseline RAS were more frequent in patients with virological failure. Development of RAS did occur after short treatment but did not result in retreatment failure with a different regimen. EudraCT no: 2017-005179-21.